The first children have been treated in the younger age group of the ProTrans-Young study

October 1, 2024

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), announces that the first four children in the 7–11 year age group have been treated in the latest phase of the ProTrans-Young study. An additional four children have been screened and are expected to begin their treatment shortly. These advancements mark an important milestone in the progress of the study, which is proceeding faster than anticipated.

“There is a high level of interest in the study, and many are signing up from all over the country,” comments Karin Kjellström, research nurse at Uppsala University Hospital. The study aims to evaluate the efficacy and safety of ProTrans, a treatment developed to protect insulin-producing cells, which in this study is being administered for the first time to children and adolescents with newly diagnosed type 1 diabetes.

The ProTrans-Young study is a double-blind, randomized, and placebo-controlled trial divided into two phases. In the first phase (Phase Ib), all patients, including those aged 7–18 years, were treated to ensure the safety of the treatment. The second phase (Phase IIb) includes a total of 60 children and adolescents, with 30 treated with ProTrans and 30 with placebo. The treatment of the first 30 patients aged 12–21 years has already been completed, and the safety data has been thoroughly reviewed and approved by the study’s safety committee.

The purpose of the ProTrans treatment is to halt the autoimmune destruction of insulin-producing cells in children and adolescents, slowing the disease progression and reduce the risk of serious complications associated with type 1 diabetes. The study aims to demonstrate that the treatment can preserve a greater portion of the body’s own insulin production, which would result in improved blood sugar regulation, reduced associated illnesses and thereby a better quality of life for the young patients.

For more information about the study and participation, please visit: NextCell Pharma - Study Information.

Professor Per-Ola Carlsson is the principal investigator for ProTrans-Young and the study is sponsored by Uppsala University. NextCell continues to contribute ProTrans, placebo, as well as support for logistics, documentation, and expert competence. The cells used for the production of ProTrans are of the same type as the cells that the subsidiary Cellaviva collects for family stem cell banking.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell is also a 100% owner of the daughter company, QVance which will offer quality control analytics for advanced therapy developers.

Download attachmentRead full press release on Cision (external link)
2018-02-16
NextCell Pharma files patent application
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorithm is based on multiple functional assays used to identify and select cells and donors with specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple donors. The pooling process supports the production of large batches. The combination
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorith...
Read moreRead more
2018-01-31
NextCell Pharma changes ticker to NXTCL
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications and company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will remain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation.
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in gener...
Read moreRead more
2018-01-24
First diabetes patient treated with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years. The clinical trial started on November 28th, 2017 and after clinical assessment and baseline data collection, the first patient has now been treated (first-in-human) with ProTrans stem cells. The first part of the study is a three-step dose escalation with three patients in each
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a max...
Read moreRead more
2017-11-29
NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production are candidates for participation in the trial. NextCell Pharma has reached a new level as a company. I would like to thank all the
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving Pr...
Read moreRead more
2017-11-14
Today Nextcell Pharma publishes its annual report 2016-2017
NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com
NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com...
Read moreRead more
2017-10-31
NextCell Pharma updates on its situation in its fourth quarter report
NextCell Pharma AB ("NEXTCL", "NextCell") today releases its Q4 / year-end report (June 1st - August 31st  / September 1st - August 31st). This is the first quarterly report since the listing on Aktietorget. The company reports a loss of SEK -4,757,996 in its fourth quarter and a loss of SEK -13,245,206 for the entire financial year. The remaining cash at August 31st was approximately 16 MSEK. The perhaps most important event during the fourth quarter was the listing on Aktietorget on July 13th and the associated listing issue, which was subscribed to approximately 18 MSEK, corresponding to
NextCell Pharma AB ("NEXTCL", "NextCell") today releases its Q4 / year-end report (June 1st - August 31st  / September 1st - August 31st). This is the first quarterly report since the listing on Aktietorget. The company reports a loss of SEK -4,757,996 in its fourth quarter and a loss of SEK -13,...
Read moreRead more
2017-10-17
NextCell Pharma's stem cell study in Type 1 Diabetes gets green light from the Medical Products Agency
NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans. For more information regarding the clinical trial, please see press release from 15th of September. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2017.
NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans. For more information regarding the clinical trial, please see press release from 15th of September. This inform...
Read moreRead more
2017-10-11
Family saving of stem cells at Underbara Barn held atStockholm International Fair and Congresses Centre,13-15 October, 2017
For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from the umbilical cord. Cellaviva is Sweden's first and only biobank for family-saving of stem cells and is owned by the stem cell company NextCell Pharma AB (NEXTCL). The applications for stem cell therapy are rapidly growing in modern medicine. Cells from family members are preferred for the treatment
For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from ...
Read moreRead more